Literature DB >> 16322290

Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid.

Jinong Li1, Jing Zhao, Xiaodong Yu, Julie Lange, Henry Kuerer, Savitri Krishnamurthy, Eric Schilling, Seema A Khan, Saraswati Sukumar, Daniel W Chan.   

Abstract

PURPOSE: To establish a comprehensive proteomic approach for biomarker discovery and validation in breast fluid. EXPERIMENTAL
DESIGN: A total of 95 specimens from three institutions were used including 10 nipple aspiration fluid (5 stage I/II cancerous breasts and 5 age-matched healthy controls), 42 ductal lavage fluid from 14 patients with unilateral stage I/II cancer (25 from 9 cancerous breasts and 17 from 7 contralateral breasts), and 42 ductal lavage fluid from 14 high-risk women (multiple ducts repeated lavage). Differentially expressed protein/peptides were discovered by proteomic analysis of training sample, using ProteinChip arrays and surface-enhanced laser desorption ionization (SELDI) time-of-flight mass spectrometry, and validated on independently collected testing samples. After protein identification, ELISA was done to confirm the SELDI findings.
RESULTS: We were able to obtain reproducible protein profiles using minimal amount of protein (1 mug) by applying an optimized chip protocol and SELDI. We were able to select cancer-associated biomarkers despite large individual variability by applying both unsupervised and supervised cluster analysis. Furthermore, we were able to train and test candidate biomarkers on independently collected samples and identified one component of a multimarker panel as human neutrophil peptides 1 to 3.
CONCLUSIONS: Breast fluid is a rich source of breast cancer biomarkers. In combination with high-throughput novel proteomic profiling technology and multicenter study design, markers that are highly specific to breast cancer can be discovered and validated. Our observations also suggest that persistent elevation of human neutrophil peptide in high-risk women may imply early onset of cancer not yet detectable by current detection method. Proof of this hypothesis requires follow-up on a larger study population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322290     DOI: 10.1158/1078-0432.CCR-05-1538

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Omics-based molecular target and biomarker identification.

Authors:  Zhang-Zhi Hu; Hongzhan Huang; Cathy H Wu; Mira Jung; Anatoly Dritschilo; Anna T Riegel; Anton Wellstein
Journal:  Methods Mol Biol       Date:  2011

Review 2.  miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.

Authors:  Bethany N Hannafon; Wei-Qun Ding
Journal:  Am J Pathol       Date:  2017-12-12       Impact factor: 4.307

Review 3.  Contributions of advanced proteomics technologies to cancer diagnosis.

Authors:  Sergio Ciordia; Vivian de Los Ríos; Juan-Pablo Albar
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

4.  Microdialysis combined with proteomics for protein identification in breast tumor microenvironment in vivo.

Authors:  Baogang J Xu; Wenwei Yan; Bojana Jovanovic; Aubie K Shaw; Qi A An; Jimmy Eng; Anna Chytil; Andrew J Link; Harold L Moses
Journal:  Cancer Microenviron       Date:  2010-04-13

5.  Protein Biomarkers for Breast Cancer Risk Are Specifically Correlated with Local Steroid Hormones in Nipple Aspirate Fluid.

Authors:  Ali Shidfar; Tolulope Fatokun; David Ivancic; Robert T Chatterton; Seema A Khan; Jun Wang
Journal:  Horm Cancer       Date:  2016-04-19       Impact factor: 3.869

Review 6.  Epigenetic targeting in breast cancer: therapeutic impact and future direction.

Authors:  M B Lustberg; B Ramaswamy
Journal:  Drug News Perspect       Date:  2009-09

Review 7.  Mammary ductoscopy in the current management of breast disease.

Authors:  Sarah S K Tang; Dominique J Twelves; Clare M Isacke; Gerald P H Gui
Journal:  Surg Endosc       Date:  2010-12-18       Impact factor: 4.584

8.  Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach.

Authors:  Daniel Böhm; Ksenia Keller; Julia Pieter; Nils Boehm; Dominik Wolters; Wulf Siggelkow; Antje Lebrecht; Marcus Schmidt; Heinz Kölbl; Norbert Pfeiffer; Franz-Hermann Grus
Journal:  Oncol Rep       Date:  2012-06-01       Impact factor: 3.906

9.  Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer.

Authors:  Lei Zhang; Hua Xiao; Scott Karlan; Hui Zhou; Jenny Gross; David Elashoff; David Akin; Xinmin Yan; David Chia; Beth Karlan; David T Wong
Journal:  PLoS One       Date:  2010-12-31       Impact factor: 3.240

10.  Paired ductal carcinoma in situ and invasive breast cancer lesions in the D-loop of the mitochondrial genome indicate a cancerization field effect.

Authors:  Andrea Maggrah; Kerry Robinson; Jennifer Creed; Roy Wittock; Ken Gehman; Teresa Gehman; Helen Brown; Andrew Harbottle; M Kent Froberg; Daniel Klein; Brian Reguly; Ryan Parr
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.